<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03196791</url>
  </required_header>
  <id_info>
    <org_study_id>Debloqs_GC</org_study_id>
    <nct_id>NCT03196791</nct_id>
  </id_info>
  <brief_title>Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient</brief_title>
  <official_title>A Double-blind, Randomized and Controlled Trial to Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the impact of muscle relaxation during laparoscopic
      gastrectomy on oncological benefit, especially with obese patients over BMI 25. The primary
      endpoint is number of harvested lymph node that is critical point regarding quality of
      surgery in gastric cancer treatment. The secondary endpoint is intraoperative bleeding,
      surgeons' satisfaction.

      The patients were randomly assigned to two groups using a computer-generated randomization
      table : 196 persons

        -  Deep neuromuscular block group (98persons)

        -  Moderate neuromuscular group (98persons)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2017</start_date>
  <completion_date type="Anticipated">August 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Harvested lymph node number</measure>
    <time_frame>within 7 days after operation</time_frame>
    <description>Number of lymph nodes obtained after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical rating score, intraoperative blood loss amount</measure>
    <time_frame>immediately after the operation</time_frame>
    <description>Surgical rating score at Four Times during LN dissection, intraoperative blood loss amount</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Deep neuromuscular block group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex sodium 4mg/kg/IV after operation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate neuromuscular group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex sodium 2mg/kg/IV after operation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex Sodium</intervention_name>
    <description>INDICATIONS AND USAGE BRIDION® is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. BRIDION (sugammadex) injection is a sterile, clear, colorless to slightly yellow-brown, non-pyrogenic aqueous solution intended for intravenous infusion.
DOSAGE AND ADMINISTRATION BRIDION (sugammadex) injection, for intravenous use, should be administered by trained healthcare providers familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents (NMBA) and neuromuscular block reversal agents.</description>
    <arm_group_label>Deep neuromuscular block group</arm_group_label>
    <arm_group_label>Moderate neuromuscular group</arm_group_label>
    <other_name>Bridion®, MSD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gastric cancer patients with laparoscopic subtotal gastrectomy

          -  19-75 years

          -  Body mass index(BMI) &gt; 25kg/m2

          -  American Society of Anesthesiologists I-III

        Exclusion Criteria:

          -  American Society of Anesthesiologists Class IV

          -  End stage renal disease (ESRD) patient

          -  Patients with allergy to muscle relaxants

          -  Patients with diseases that may affect muscle relaxation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung soo Park, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sung soo Park, MD,PhD</last_name>
    <phone>+82-2-920-6772</phone>
    <email>kugspss@korea.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyub Huh, MD,PhD</last_name>
    <phone>+82-2-920-5632</phone>
    <email>clumania@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sungsoo Park</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Anam Hospital</investigator_affiliation>
    <investigator_full_name>Sungsoo Park</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

